Follow The Filings

TMDX Transmedics Group Inc.

Health Care, filed as TRANSMEDICS GROUP INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 1

  • 1 Owner
  • Max 0.1%
  • $11M
  • 1 add 1 exit

In 2026 Q2 Davidson Kempner Capital Management added to Transmedics Group, while Polen Capital Management sold out.

Who owns this now

Largest portfolio weights among holders, up to 0.1% (Davidson Kempner Capital Management). Not free-float ownership.

  1. Davidson Kempner Capital Mana... Add 0.13%

Who owns TMDX

Sorted by value, long equity only, as of 2026 Q2.

History
Davidson Kempner Capital Management 0.13% Add +14.0% 166,900 $11M History
Polen Capital Management exited 2026 Q2 Last 2026 Q1 0.01% Exit −0.01% 7,422 $738K History

1 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by TMDX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All TMDX insider trades
  • $1.1M bought by 2 insiders
  • $2.9M sold by 4 insiders outside a trading plan
  • $540K sold by 1 insider under 10b5-1 plans
  1. David Weill Director
    Buy
    $109K 1,336 shares at $81.63 +8.9% to stake
    Traded Sep 11 Filed Sep 14
    ↗
  2. Stephanie Lovell Director
    Sale
    $178K 1,193 shares at $149.62 29% of stake
    Traded Mar 4 Filed Mar 6
    ↗
  3. David Weill Director
    Sale
    $524K 3,571 shares at $146.82 23% of stake
    Traded Mar 4 Filed Mar 6
    ↗
  4. Gerardo Hernandez CFO
    Sale
    $1.1M 7,236 shares at $147.21 33% of stake
    Traded Mar 4 Filed Mar 4
    ↗
  5. David Weill Director
    Sale
    $693K 5,000 shares at $138.64 29% of stake
    Traded Dec 3, 2025 Filed Dec 5, 2025
    ↗
  6. Anil P. Ranganath See remarks
    Sale
    $436K 3,000 shares at $145.22 18% of stake
    Traded Nov 25, 2025 Filed Nov 26, 2025
    ↗
  7. Waleed H Hassanein CEO
    Buy
    $1M 8,775 shares at $114.00 +1.8% to stake
    Traded Nov 17, 2025 Filed Nov 18, 2025
    ↗
  8. Edward M Basile Director
    Planned sale
    $540K 4,142 shares at $130.45 59% of stake
    Traded Oct 29, 2025 Filed Oct 31, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 12 stock grants, 7 option exercises, 5 sales to cover taxes, 1 share withholding for taxes, and 1 gift.

SEC filings

Recent issuer filings from EDGAR, 17 shown.

Filed Form Detail Links
8-K 5.02,7.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.07,9.01 Filing Doc
DEFA14A Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 5.02 Filing Doc
8-K 1.01,8.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Gross profit $154.09M $262.08M $362.81M
Net income -$25.03M $35.46M $190.29M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $510.65M $497.22M $637.78M
Total non-current assets * $195.39M $306.86M $430.59M
Total assets $0.706B $0.804B $1.07B
Total current liabilities $54.93M $59.91M $89.3M
Total non-current liabilities * $513.91M $515.56M $505.97M
Total equity $137.2M $228.6M $473.1M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$13.03M $48.8M $192.84M
Cash from investing -$193.95M -$129.3M -$59.25M
Cash from financing $400.42M $22.87M $16.86M
Net change in cash $193.63M -$58.16M $151.72M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.